Abstract: Background: Actinic keratosis (AK) represents a risk of progression to squamous cell carcinoma. Ingenol mebutate gel is a novel therapeutic option for field-directed treatment. oBjectives: To evaluate the safety, tolerability and patients' perspectives, related to the therapeutic success of managing AKs on the face and scalp with ingenol mebutate gel in Brazilian individuals. Methods: This was an observational, retrospective and descriptive study of 68 areas of actinic keratosis on the face and scalp treated with Ingenol mebutate gel involving a total of 37 patients. The drug was applied for three consecutive days on an area of of 25 cm 2 and documentation was performed on baseline and days 4, 8, 15, 60 and 180. On day 4, the composite local skin reaction score was calculated. At the end, a questionnaire was applied to evaluate patients' perspectives about the treatment. results: Adherence was 100%, no serious adverse events were recorded and the mean composite local skin reaction score (standard deviation) was 8.61±4.22. The treatment was considered optimum by 75.68% of the patients. study liMitations: Calculation of composite local skin reaction score performed only on the fourth day. conclusions: Treatment with ingenol mebutate gel was considered safe and tolerable in Brazilian subjects. Patients had a maximum adherence rate and a great improvement in self-esteem. The results of this research reproduce the findings of the literature.
INTRODUCTION
Actinic keratosis (AK), or solar keratosis, is an intraepidermal neoplasia induced by chronic exposure of the skin to ultraviolet radiation. [1] [2] [3] Considered the third most frequent disease in dermatologic consultations in the United States (US) and the fourth in Brazil, it represents the number one dermatosis in the elderly. 4, 5 Its prevalence is variable, ranging between 11% and 25% in northern hemisphere countries, while in Australia it is between 40 and 60%. 6 In the US, it has been estimated that 58 million individuals have AK, resulting in more than one billion of dollars in treatment costs. 7 Epidemiological studies in our country report a ratio between 2.9 to 13.4% in prevalence, according to population and geographic area. 3, 5, 8 It is a major public health problem due to the cumulative Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives
In terms of treatment, two modalities can be used to treat AKs: (i) direct destruction of the lesion (cryotherapy, shaving, curettage and eletrocoagulation, laser) and (ii) cancerization field treatment (5-fluorouracil (5-FU), imiquimod, diclofenac gel, photodynamic therapy, ingenol mebutate). 15 The need to include the field-directed approach is recommended by guidelines of some countries when the number of of contiguous lesions is greater than two or three in a 25 cm 2 area. [17] [18] [19] [20] [21] This is supported by the concept that subclinical dysplastic lesions are present in the circumjacent area chronically sun exposed and has the potential to progress to invasive SCC. [16] [17] [18] Among efficacious treatment options in the literature for AK and field cancerization, ingenol mebutate (IM) gel is a novel agent, approved in 2012 by the Food and Drug Administration and European Medicines Agency. 10 Since March 2016, it has been available in the Brazilian market. 22 It consists of a macrocyclic diterpene ester derived from the Euphorbia peplus plant sap, with a dual mechanism of action: (i) direct and fast cell necrosis due to mitochondrial membrane rupture of proliferating keratinocytes and (ii) neutrophil and antibody-dependent specific cellular cytotoxicity, a process that might eliminate remaining eventually dysplastic keratinocytes. 7, [23] [24] [25] [26] It is recommended to be applied on a 25 cm 2 skin area once a day for two consecutive days on lesions on the trunk or extremities (0.05% gel) and once a day for three consecutive days for those on the face and scalp (0.015% gel). The efficacy for AKs on the face, scalp, trunk and extremities is confirmed by four randomized placebo-controlled trials. 27 Treatment duration is much shorter (2-3 days) in comparison to treatments recommended for weeks to months such as imiquimod, 5-FU and diclofenac. 27 For that reason, patient adherence to this new therapeutic option tends to be higher. 10, 20 Long term (12 months) tolerability and safety of ingenol mebutate for the treatment of AKs have been evaluated in four phase 3 studies. [27] [28] [29] In Brazil, 100 patients have been evaluated in a randomized trial comparing the 0.015% ingenol gel (n=50) with 5-FU cream (n=50). 30 Ingenol gel was considered safe in facial lesions and both the duration and local skin reactions in this group were shorter. 30 Midand long-term follow-up studies in Brazilian and Latin American patients have not been performed yet, neither observational ones including larger number of cases and other body sites treated, such as the scalp, for instance.
The purpose of this study was to evaluate the safety, tolerability and patients' perspectives, related to the therapeutic success of managing AKs on the face and scalp with ingenol mebutate gel in Brazilian individuals. 
METHODS

Participants and Study Design
Procedures
The treatment of all patients followed a standard proce- 
Ethical aspects
The present study was approved by the Ethics and Local
Research Committee, identified as CAAE 61182716.6.0000.5412. All the procedures performed complied with the standards of Resolution 196/96 of the National Health Council. All individuals were duly informed and agreed with the procedures performed.
Statistical analysis
All data collection was systematized using Numbers software, version 4. 
Local Skin Reactions
The mean (±SD) composite LSR score in the 68 treatments was 8. (Table 1) .
Patients' Perspectives
Regarding the patients' perspectives about IM treatment, 75.68% of them considered it great (Q1); discomfort with the treatment (Q2) was reported as reasonable in 40.54%, and 13.51% of the patients denied any discomfort from the treatment (Chart 1 and Graph 2). Of all ten adverse reactions studied (Q3), erythema and local pruritus, in the same percentage (16%), were the ones that most disturbed the patients. The report of no adverse reactions was also recorded by five patients (14%). Almost all patients (97.30%) reported improved self-esteem after treatment completion (Q4) (Graph 2).
The final score (0-10) referring the treatment (Q5) reported by the patients ranged from 7 to 10, and 9.4 was the global average.
During this study no serious adverse events were recorded.
There was no need for urgent/emergency care and a single case of local acute bacterial infection was diagnosed and promptly treated with oral azithromycin. Self-administration of analgesics (single dose of dipyrone) was performed by three patients due to mild headache. Regarding the need to use other systemic medications, no drug has been prescribed for any reason related to IM treatment. consecutive days on an area of 100 cm 2 of the forearm. 35 As a result of this research, there was no systemic absorption of ingenol mebutate (and its two metabolites) and a good tolerability profile was observed at a concentration four times higher that recommended in clinical studies. 35, 36 This evidence supports the safe use of this drug even in patients in advanced age, with multiple comorbidities and under the use of numerous medications. In our study, involving a Treatment duration and its adverse effects are considered the most preponderant predictive factors of non-adherence. 20, 37 Therefore, when considering the efficacy of a drug, which was established in randomized clinical trials (RCTs), one should also estimate the real risk of non-adherence in longer modalities. 20, 38 As a result of this, clinical follow-up studies are also necessary in the post-marketing phase. 39 Due to the fact that ingenol mebutate has a two or three consecutive-day regimen, patient adherence rates are often close to a 100% (as observed in our study). 27 The efficacy of IM in clinical practice ("real world") has been shown to be equivalent to that established in RCTs. 27, 40 Recently, an international consensus of eight US, Brazilian, European and Australian AK expert dermatologists has concluded that shorter and better-managed treatments have the potential to substantially increase effectiveness in the real world. 
DISCUSSION
CONCLUSION
The treatment of face and scalp AKs with 0.015% ingenol mebutate gel was considered safe and tolerable in Brazilian subjects.
The perspective, from the patients' point of view, was positive, with a high rate of adherence to treatment and a great improvement in self-esteem. q
